Featured Publications
Dose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT)
Tsai C, McBride S, Riaz N, Kang J, Spielsinger D, Waldenberg T, Yu Y, Chen L, Zakeri K, Wong R, Dunn L, Sherman E, Lee N. Dose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT). International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s142-s143. DOI: 10.1016/j.ijrobp.2021.07.321.Peer-Reviewed Original ResearchConcurrent chemoradiationDe-escalation strategiesOropharyngeal cancerGross diseaseNodal recurrenceDisease recurrenceOPC patientsLevel IbHPV-positive OPC patientsLocoregional recurrence-free survivalElective nodal regionsFavorable locoregional controlFeeding tube dependenceHigh-dose cisplatinPositive oropharyngeal cancerPrimary concurrent chemoradiationRecurrence-free survivalNode-positive neckFeeding tube placementLong-term resultsNode-negative neckDe-escalation approachMATERIAL/METHODSHigh control ratesRadiation treatment plans
2022
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
Youssef I, Yoon J, Mohamed N, Zakeri K, Press R, Yu Y, Kang J, Wong R, Tuttle R, Shaha A, Sherman E, Lee N. Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. International Journal Of Particle Therapy 2022, 9: 20-30. PMID: 36060412, PMCID: PMC9415751, DOI: 10.14338/ijpt-22-00005.1.Peer-Reviewed Original ResearchPercent of patientsLocal-regional recurrenceThyroid cancerRadiation therapyGross diseaseOverall survivalPercutaneous endoscopic gastrostomy tubeProton therapyProton beam radiation therapyAcute grade 3Central neck compartmentFavorable therapeutic ratioIntensity-modulated radiation therapyBeam radiation therapyProton beam therapyConcurrent chemotherapyPalliative radiationUnresectable diseaseAdjuvant radiationDefinitive radiationT4 diseaseMetastatic diseaseNeck compartmentRegional recurrenceUpper mediastinumEvaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow